HEALTHSTAT NEWS
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
Revolution Medicines has started shipping its experimental pancreatic cancer drug daraxonrasib to patients under an FDA-authorized early access program. The drug, not yet approved, showed in a Phase 3 trial that patients lived nearly twice as long as those receiving standard chemotherapy.
Mentioned
Related Signal
Adjacent reporting
- Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug
- FDA expands access to drug helping pancreatic cancer patients
- FDA expanding access to pancreatic cancer drug to some patients
- WATCH: How a new drug could lengthen lives of pancreatic cancer patients
- Experimental treatment for pancreatic cancer could be breakthrough for patients
- New pancreatic cancer pill could reshape treatment as early trial results stun researchers